GSK plc
GSK
$40.32
$0.270.67%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | 21.95% | -104.07% | -27.21% | -26.69% | -75.24% |
Total Depreciation and Amortization | -50.66% | 68.81% | 42.48% | -10.42% | 227.64% |
Total Amortization of Deferred Charges | 7.16% | -- | -- | -- | 5.24% |
Total Other Non-Cash Items | 305.44% | -365.39% | -369.06% | -146.07% | -68.42% |
Change in Net Operating Assets | -128.73% | 562.89% | 52.83% | 70.45% | 260.32% |
Cash from Operations | -24.87% | 0.08% | -14.18% | 1,787.60% | 77.44% |
Capital Expenditure | -15.40% | -4.84% | -2.82% | -11.15% | -17.35% |
Sale of Property, Plant, and Equipment | 798.43% | -90.66% | -32.81% | -85.08% | -94.43% |
Cash Acquisitions | -3,250.75% | 93.47% | 97.63% | -75,295.83% | 97.45% |
Divestitures | 26.36% | -54.16% | -111.02% | 47.79% | 69.15% |
Other Investing Activities | -177.19% | -212.81% | 67.72% | 591.11% | 724.65% |
Cash from Investing | -530.47% | -53.02% | 180.50% | 61.86% | 152.49% |
Total Debt Issued | 195.17% | -- | -- | -- | -214.27% |
Total Debt Repaid | 18.23% | -25.05% | 15.58% | -98.95% | 16.67% |
Issuance of Common Stock | -100.00% | -- | -66.67% | 125.00% | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -11.08% | -10.94% | -17.97% | -6.87% | 8.15% |
Other Financing Activities | -102.91% | 74.23% | 16.58% | 0.00% | 8.44% |
Cash from Financing | 75.83% | 27.67% | -5,249.55% | -248.10% | -183.93% |
Foreign Exchange rate Adjustments | 121.23% | -251.93% | 85.86% | 36.00% | -178.17% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 338.65% | 950.78% | -7.49% | 59.95% | -334.70% |